Prurisol Phase 2b in Moderate to Severe Chronic Plaque Psoriasis

Phase 2, randomised, double-blind trial of Abacavir hydroxyacetate in plaque psoriasis (3 arms), sponsored by Innovation Pharmaceuticals Inc. Primary endpoints: Proportion of participants achieving at least a 75% reduction from baseline in PASI score at 12 weeks and Incidence of Treatment-Emergent Adverse Events at 16 weeks. Started Nov 2016; status: completed.